Robert Z. Orlowski, MD, PhD, from MD Anderson Cancer Center discusses myeloma drugs for 2018 and anti-body drug conjugates, Bi-specific T-cell engagers, etc. at the 2017 American Society of Hematology.
Myeloma drugs for 2018 – Anti-body drug conjugates, Bi-specific T-cell engagers, etc.
